BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ. [DOI: 10.1136/bmj.m3544] [Cited by in Crossref: 13] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Li J, Wang W, Zhou Y, Liu L, Zhang G, Guan K, Cui X, Liu X, Huang M, Cui G, Sun R. m6A Regulator-Associated Modification Patterns and Immune Infiltration of the Tumor Microenvironment in Hepatocarcinoma. Front Cell Dev Biol 2021;9:687756. [PMID: 34277630 DOI: 10.3389/fcell.2021.687756] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Yu B, Zhou S, Liang H, Ye Q, Wang Y. Development and Validation of a Novel Circulating miRNA-Based Diagnostic Score for Early Detection of Hepatocellular Carcinoma. Dig Dis Sci 2021. [PMID: 33982217 DOI: 10.1007/s10620-021-07031-0] [Reference Citation Analysis]
3 Xia X, Zhang H, Xia P, Zhu Y, Liu J, Xu K, Yuan Y. Identification of Glycolysis-Related lncRNAs and the Novel lncRNA WAC-AS1 Promotes Glycolysis and Tumor Progression in Hepatocellular Carcinoma. Front Oncol 2021;11:733595. [PMID: 34527595 DOI: 10.3389/fonc.2021.733595] [Reference Citation Analysis]
4 Salah H, Al-Mohammed HI, Mayhoub FH, Sulieman A, Alkhorayef M, Abolaban FA, Khandaker MU, Bradley DA. Assessment of Patient's Radiation Exposures Resulted from PET/CT 18F-FCH and 68GA-PSMA Procedures. Radiat Prot Dosimetry 2021:ncab077. [PMID: 34144608 DOI: 10.1093/rpd/ncab077] [Reference Citation Analysis]
5 Liu X, Guo R, Tian J. Association of Plasma Fibrinogen Levels on Postoperative Day 1 with 2-Year Survival of Orthotopic Liver Transplantation for HBV-Related HCC. Lab Med 2021:lmab052. [PMID: 34268570 DOI: 10.1093/labmed/lmab052] [Reference Citation Analysis]
6 Du P, Luo K, Li G, Zhu J, Xiao Q, Li Y, Zhang X. PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis. Int J Med Sci 2021;18:3588-98. [PMID: 34522186 DOI: 10.7150/ijms.62467] [Reference Citation Analysis]
7 Wang Z, Rehman AU, Qin X, Zhu C, Wu S, Bukhari I. PI3K/AKT/mTOR Pathway-Associated Genes Reveal a Putative Prognostic Signature Correlated with Immune Infiltration in Hepatocellular Carcinoma. Disease Markers 2022;2022:1-18. [DOI: 10.1155/2022/7545666] [Reference Citation Analysis]
8 Yin L, Zhou L, Gao S, Feng Y, Zhu H, Xiang J, Xu R. Classification of Hepatocellular Carcinoma Based on N6-Methylandenosine–Related lncRNAs Profiling. Front Mol Biosci 2022;9:807418. [DOI: 10.3389/fmolb.2022.807418] [Reference Citation Analysis]
9 Ma H, Li Z, Yuan J, Zhang L, Xie X, Yin X, Chen R, Ren Z. Extrapolating Prognostic Factors of Primary Curative Resection to Postresection Recurrences Hepatocellular Carcinoma Treatable by Radiofrequency Ablation. Gastroenterol Res Pract 2021;2021:8878417. [PMID: 33488700 DOI: 10.1155/2021/8878417] [Reference Citation Analysis]
10 Liu L, Liu B, Yu J, Zhang D, Shi J, Liang P. Development of a Toll-Like Receptor-Based Gene Signature That Can Predict Prognosis, Tumor Microenvironment, and Chemotherapy Response for Hepatocellular Carcinoma. Front Mol Biosci 2021;8:729789. [PMID: 34621787 DOI: 10.3389/fmolb.2021.729789] [Reference Citation Analysis]
11 Wen C, Tang J, Luo H. Development and Validation of a Nomogram to Predict Cancer-Specific Survival for Middle-Aged Patients With Early-Stage Hepatocellular Carcinoma. Front Public Health 2022;10:848716. [DOI: 10.3389/fpubh.2022.848716] [Reference Citation Analysis]
12 Yang S, Wang D, Zhang X, Sun Y, Zheng B. cRGD peptide-conjugated polyethylenimine-based lipid nanoparticle for intracellular delivery of siRNA in hepatocarcinoma therapy. Drug Deliv 2021;28:995-1006. [PMID: 34042551 DOI: 10.1080/10717544.2021.1928794] [Reference Citation Analysis]
13 Zhu J, Zhang Y, Chen X, Bian Y, Li J, Wang K. The Emerging Roles of LINC00665 in Human Cancers. Front Cell Dev Biol 2022;10:839177. [DOI: 10.3389/fcell.2022.839177] [Reference Citation Analysis]
14 Amponsah-Dacosta E. Hepatitis B virus infection and hepatocellular carcinoma in sub-Saharan Africa: Implications for elimination of viral hepatitis by 2030? World J Gastroenterol 2021; 27(36): 6025-6038 [PMID: 34629817 DOI: 10.3748/wjg.v27.i36.6025] [Reference Citation Analysis]
15 Chen S, Lai H, Zhao J, Chen B, Li Y, Li Y, Li Q, Zheng Q, Huang S, Zhu X. The viral expression and immune status in human cancers and insights into novel biomarkers of immunotherapy. BMC Cancer 2021;21:1183. [PMID: 34740324 DOI: 10.1186/s12885-021-08871-9] [Reference Citation Analysis]
16 Dai T, Ye L, Yu H, Li K, Li J, Liu R, Lu X, Deng M, Li R, Liu W, Yang Y, Wang G. Regulation Network and Prognostic Significance of Aldo-Keto Reductase (AKR) Superfamily Genes in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:997-1021. [PMID: 34513744 DOI: 10.2147/JHC.S323743] [Reference Citation Analysis]
17 Cohen O, Aleem M, Wolberink S, Perenyei MA. Giant pedunculated liver mass: primary hepatocellular carcinoma masquerading as hepatic haemangioma. BMJ Case Rep 2021;14:e242625. [PMID: 34593547 DOI: 10.1136/bcr-2021-242625] [Reference Citation Analysis]
18 Wang Y, Chen J, Tian J, Wang G, Luo W, Huang Z, Huang Y, Li N, Guo M, Fan X. Tryptophan-sorbitol based carbon quantum dots for theranostics against hepatocellular carcinoma. J Nanobiotechnol 2022;20. [DOI: 10.1186/s12951-022-01275-2] [Reference Citation Analysis]
19 Du Y, Liu D, Du Y. Recent advances in hepatocellular carcinoma therapeutic strategies and imaging-guided treatment. J Drug Target 2021;:1-15. [PMID: 34727794 DOI: 10.1080/1061186X.2021.1999963] [Reference Citation Analysis]
20 Lyu LH, Zhang CY, Yang WJ, Jin AL, Zhu J, Wang H, Liu T, Wang BL, Cheng JW, Yang XR, Guo W. Hsa_circ_0003945 promotes progression of hepatocellular carcinoma by mediating miR-34c-5p/LGR4/β-catenin axis activity. J Cell Mol Med 2022. [PMID: 35170199 DOI: 10.1111/jcmm.17243] [Reference Citation Analysis]
21 Fan Y, Yu Y, Wang X, Hu M, Du M, Guo L, Sun S, Hu C. Texture Analysis Based on Gd-EOB-DTPA-Enhanced MRI for Identifying Vessels Encapsulating Tumor Clusters (VETC)-Positive Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:349-59. [PMID: 33981636 DOI: 10.2147/JHC.S293755] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Kelly D, Fernández-Ortega P, Arjona ET, Daniele B. The role of nursing in the management of patients with renal and hepatic cancers: A systematic literature review. Eur J Oncol Nurs 2021;55:102043. [PMID: 34655916 DOI: 10.1016/j.ejon.2021.102043] [Reference Citation Analysis]
23 Chen H, Tao M, Li D, Han J, Cheng C, Ma Y, Wu Y, Shelat VG, Tustumi F, Satapathy SK, Kang KJ, Wang Q. An evaluation of the reporting quality in clinical practice guidelines for hepatocellular carcinoma using the RIGHT checklist. Ann Transl Med 2021;9:1004. [PMID: 34277804 DOI: 10.21037/atm-21-2611] [Reference Citation Analysis]
24 Liu P, Han B, Zhang Y, Wang X, Ahmad S. Network Pharmacology-Based Strategy to Investigate the Mechanisms of Lenvatinib in the Treatment of Hepatocellular Carcinoma. Computational Intelligence and Neuroscience 2022;2022:1-14. [DOI: 10.1155/2022/7102500] [Reference Citation Analysis]
25 He L, Zhang Y, Chen J, Liu G, Zhu J, Li X, Li D, Yang Y, Lee CS, Shi J, Yin C, Lai P, Wang L, Fang C. A multifunctional targeted nanoprobe with high NIR-II PAI/MRI performance for precise theranostics of orthotopic early-stage hepatocellular carcinoma. J Mater Chem B 2021;9:8779-92. [PMID: 34635903 DOI: 10.1039/d1tb01729b] [Reference Citation Analysis]
26 Deng M, Li SH, Guo RP. Recent Advances in Local Thermal Ablation Therapy for Hepatocellular Carcinoma. Am Surg 2021;:31348211054532. [PMID: 34743609 DOI: 10.1177/00031348211054532] [Reference Citation Analysis]
27 Ahn JC, Qureshi TA, Singal AG, Li D, Yang JD. Deep learning in hepatocellular carcinoma: Current status and future perspectives. World J Hepatol 2021; 13(12): 2039-2051 [DOI: 10.4254/wjh.v13.i12.2039] [Reference Citation Analysis]
28 van der Pol CB. Editorial on "Deep Learning with 3D Convolutional Neural Network for Noninvasive Prediction of Microvascular Invasion in Hepatocellular Carcinoma". J Magn Reson Imaging 2021;54:144-5. [PMID: 33554416 DOI: 10.1002/jmri.27533] [Reference Citation Analysis]
29 Guan R, Sun B, Wang Z, Zhou C, Yang Z, Gan W, Huang J, Liu G, Zhou J, Fan J, Yi Y, Qiu S. Antiviral therapy improves postoperative survival of patients with HBV-related hepatocellular carcinoma. The American Journal of Surgery 2022. [DOI: 10.1016/j.amjsurg.2022.01.008] [Reference Citation Analysis]
30 Shuyao W, Mingyang B, Feifei M, Xiaoqin H. CK19 Predicts Recurrence and Prognosis of HBV Positive HCC. J Gastrointest Surg 2021. [PMID: 34506016 DOI: 10.1007/s11605-021-05107-w] [Reference Citation Analysis]
31 Harkus U, Wankell M, Palamuthusingam P, Mcfarlane C, Hebbard L. Immune checkpoint inhibitors in HCC: cellular, molecular and systemic data. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.01.005] [Reference Citation Analysis]
32 Zhu B, Gu S, Wu X, He W, Zhou H. Bioinformatics analysis of tumor-educated platelet microRNAs in patients with hepatocellular carcinoma. Biosci Rep 2021;41:BSR20211420. [PMID: 34806748 DOI: 10.1042/BSR20211420] [Reference Citation Analysis]
33 Chen H, Zhang C, Zhou Q, Guo Y, Ren Z, Yu Z, Del Turco S. Integrated Bioinformatic Analysis Identifies TIPIN as a Prognostic Biomarker in Hepatocellular Carcinoma. Disease Markers 2022;2022:1-15. [DOI: 10.1155/2022/5764592] [Reference Citation Analysis]
34 Liu M, Huang Q, Zhu Y, Chen L, Li Y, Gong Z, Ai K. Harnessing reactive oxygen/nitrogen species and inflammation: Nanodrugs for liver injury. Materials Today Bio 2022. [DOI: 10.1016/j.mtbio.2022.100215] [Reference Citation Analysis]
35 Deng T, Li J, He B, Chen B, Liu F, Chen Z, Zheng J, Shi Z, Zhang T, Deng L, Yu H, Yang J, Wu L, Shan Y, Yu Z, Chen X, Wang Y, Chen G. Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer. Hepatol Int. [DOI: 10.1007/s12072-021-10279-3] [Reference Citation Analysis]
36 Feng X, Zou B, Nan T, Zheng X, Zheng L, Lan J, Chen W, Yu J. MiR-25 enhances autophagy and promotes sorafenib resistance of hepatocellular carcinoma via targeting FBXW7. Int J Med Sci 2022;19:257-66. [PMID: 35165511 DOI: 10.7150/ijms.67352] [Reference Citation Analysis]
37 Yu Y, Chen X, Zhang W, Liu J. Abnormal Expression of Centromere Protein U Is Associated with Hepatocellular Cancer Progression. Biomed Res Int 2021;2021:4051192. [PMID: 34957303 DOI: 10.1155/2021/4051192] [Reference Citation Analysis]
38 Xu JH, Guan YJ, Qiu ZD, Zhang X, Zi LL, Zhou Y, Chen C, Yu J, Zhang YC, Wang WX. System Analysis of ROS-Related Genes in the Prognosis, Immune Infiltration, and Drug Sensitivity in Hepatocellular Carcinoma. Oxid Med Cell Longev 2021;2021:6485871. [PMID: 34795841 DOI: 10.1155/2021/6485871] [Reference Citation Analysis]
39 Bai S, Chen W, Zheng M, Wang X, Peng W, Zhao Y, Wang Y, Xiong S, Cheng B. Spindle and kinetochore-associated complex subunit 3 (SKA3) promotes stem cell-like properties of hepatocellular carcinoma cells through activating Notch signaling pathway. Ann Transl Med 2021;9:1361. [PMID: 34733913 DOI: 10.21037/atm-21-1572] [Reference Citation Analysis]
40 Yao S, Ye Z, Wei Y, Jiang HY, Song B. Radiomics in hepatocellular carcinoma: A state-of-the-art review. World J Gastrointest Oncol 2021; 13(11): 1599-1615 [PMID: 34853638 DOI: 10.4251/wjgo.v13.i11.1599] [Reference Citation Analysis]
41 Zhou J, Zhu Y, Ma S, Li Y, Liu K, Xu S, Li X, Li L, Hu J, Liu Y. Bioinformatics analysis identifies DYNC1I1 as prognosis marker in male patients with liver hepatocellular carcinoma. PLoS One 2021;16:e0258797. [PMID: 34679093 DOI: 10.1371/journal.pone.0258797] [Reference Citation Analysis]
42 Xu X, Ding Y, Pan T, Gao F, Huang X, Sun Q. CT-Guided 125I Brachytherapy in the Treatment of Hepatocellular Carcinoma Refractory to Conventional Transarterial Chemoembolization: A Pilot Study. Cancer Manag Res 2021;13:3317-26. [PMID: 33883943 DOI: 10.2147/CMAR.S305422] [Reference Citation Analysis]
43 Lei Z, Cheng N, Si A, Yang P, Guo G, Ma W, Yu Q, Wang X, Cheng Z. A Novel Nomogram for Predicting Postoperative Liver Failure After Major Hepatectomy for Hepatocellular Carcinoma. Front Oncol 2022;12:817895. [DOI: 10.3389/fonc.2022.817895] [Reference Citation Analysis]
44 Wang J, Fan Z, Li J, Yang J, Liu X, Cheng J. Transcription factor specificity protein 1-mediated Serine/threonine kinase 39 upregulation promotes the proliferation, migration, invasion and epithelial-mesenchymal transition of hepatocellular carcinoma cells by activating the transforming growth factor-β1 /Smad2/3 pathway. Bioengineered 2021;12:3566-77. [PMID: 34281492 DOI: 10.1080/21655979.2021.1947939] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
45 Zeng C, Ye S, Chen Y, Zhang Q, Luo Y, Gai L, Luo B. HOXA-AS3 Promotes Proliferation and Migration of Hepatocellular Carcinoma Cells via the miR-455-5p/PD-L1 Axis. J Immunol Res 2021;2021:9289719. [PMID: 34988230 DOI: 10.1155/2021/9289719] [Reference Citation Analysis]
46 He F, Chen G, He R, Huang Z, Li J, Wu W, Chen J, Tang Y, Li D, Pan S, Feng Z, Dang Y. Expression of IER3 in hepatocellular carcinoma: clinicopathology, prognosis, and potential regulatory pathways. PeerJ 2022;10:e12944. [DOI: 10.7717/peerj.12944] [Reference Citation Analysis]
47 Debes JD, Romagnoli PA, Prieto J, Arrese M, Mattos AZ, Boonstra A, On Behalf Of The Escalon Consortium. Serum Biomarkers for the Prediction of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1681. [PMID: 33918270 DOI: 10.3390/cancers13071681] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
48 Guan MC, Wang MD, Liu SY, Ouyang W, Liang L, Pawlik TM, Xu QR, Huang DS, Shen F, Zhu H, Yang T. Early diagnosis and therapeutic strategies for hepatocellular carcinoma: From bench to bedside. World J Gastrointest Oncol 2021; 13(4): 197-215 [PMID: 33889272 DOI: 10.4251/wjgo.v13.i4.197] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Zhang J, Shang L, Jiang W, Wu W. Shikonin induces apoptosis and autophagy via downregulation of pyrroline-5-carboxylate reductase1 in hepatocellular carcinoma cells. Bioengineered 2022;13:7904-18. [PMID: 35293266 DOI: 10.1080/21655979.2022.2052673] [Reference Citation Analysis]
50 Liao R, Wei X, Che P, Yin K, Liu L. Nomograms Incorporating the CNLC Staging System Predict the Outcome of Hepatocellular Carcinoma After Curative Resection. Front Oncol 2022;11:755920. [DOI: 10.3389/fonc.2021.755920] [Reference Citation Analysis]
51 Shi H, Zhong F, Yi X, Shi Z, Ou F, Zuo Y, Xu Z. The Construction of a Prognostic Model Based on a Peptidyl Prolyl Cis-Trans Isomerase Gene Signature in Hepatocellular Carcinoma. Front Genet 2021;12:730141. [PMID: 34887898 DOI: 10.3389/fgene.2021.730141] [Reference Citation Analysis]
52 Chen S, Fu Z, Wen S, Yang X, Yu C, Zhou W, Lin Y, Lv Y. Expression and Diagnostic Value of miR-497 and miR-1246 in Hepatocellular Carcinoma. Front Genet 2021;12:666306. [PMID: 34163524 DOI: 10.3389/fgene.2021.666306] [Reference Citation Analysis]
53 Peng J, Zhang T, Wang H, Ma X. The Value of Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in the Diagnosis of Hepatocellular Carcinoma:: A Meta-Analysis. J Ultrasound Med 2021. [PMID: 34617296 DOI: 10.1002/jum.15837] [Reference Citation Analysis]